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MRI
A B S T R A C T
Background: Diagnosing frontotemporal dementia may be challenging. New methods for analysis of regional
brain atrophy patterns on magnetic resonance imaging (MRI) could add to the diagnostic assessment. Therefore,
we aimed to develop automated imaging biomarkers for differentiating frontotemporal dementia subtypes from
other diagnostic groups, and from one another.
Methods: In this retrospective multicenter cohort study, we included 1213 patients (age 67 ± 9, 48% females)
from two memory clinic cohorts: 116 frontotemporal dementia, 341 Alzheimer's disease, 66 Dementia with Lewy
bodies, 40 vascular dementia, 104 other dementias, 229 mild cognitive impairment, and 317 subjective cog-
nitive decline. Three MRI atrophy biomarkers were derived from the normalized volumes of automatically
segmented cortical regions: 1) the anterior vs. posterior index, 2) the asymmetry index, and 3) the temporal pole
left index. We used the following performance metrics: area under the receiver operating characteristic curve
(AUC), sensitivity, and specificity. To account for the low prevalence of frontotemporal dementia we pursued a
high specificity of 95%. Cross-validation was used in assessing the performance. The generalizability was as-
sessed in an independent cohort (n=200).
Results: The anterior vs. posterior index performed with an AUC of 83% for differentiation of frontotemporal
dementia from all other diagnostic groups (Sensitivity= 59%, Specificity= 95%, positive likelihood
ratio= 11.8, negative likelihood ratio= 0.4). The asymmetry index showed highest performance for separation
of primary progressive aphasia and behavioral variant frontotemporal dementia (AUC=85%,
Sensitivity= 79%, Specificity= 92%, positive likelihood ratio= 9.9, negative likelihood ratio= 0.2), whereas
the temporal pole left index was specific for detection of semantic variant primary progressive aphasia
(AUC=85%, Sensitivity= 82%, Specificity= 80%, positive likelihood ratio= 4.1, negative likelihood
ratio= 0.2). The validation cohort provided corresponding results for the anterior vs. posterior index and
temporal pole left index.
Conclusion: This study presents three quantitative MRI biomarkers, which could provide additional information
to the diagnostic assessment and assist clinicians in diagnosing frontotemporal dementia.
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Frontotemporal dementia (FTD), the second most frequent early-
onset neurodegenerative dementia disease, represents various clinical
syndromes including behavioral variant frontotemporal dementia
(bvFTD) and primary progressive aphasia (PPA) (Picard C., 2011;
Rabinovici and Miller 2010). PPA may be further subdivided into
subgroups including semantic variant PPA (svPPA) and non-fluent
variant PPA (nfvPPA) (Gorno-Tempini et al. 2011). Determining these
clinical FTD diagnoses can be challenging as the clinical symptoms and
neuropsychological profiles overlap with other types of dementia, e.g.,
AD (Mendez et al. 2013; Ossenkoppele et al. 2015; Smits et al. 2012;
Vijverberg et al. 2016). However, accurate and early diagnosis is im-
portant to ensure optimal counseling, care, and treatment.
Frontal and temporal lobe atrophy on magnetic resonance imaging
(MRI), with relative preservation of posterior areas, represent the
imaging hallmark of frontotemporal lobar degeneration (the neuro-
pathological changes underlying FTD) (Neary et al. 1998). For bvFTD
the areas with the most pronounced gray matter atrophy are typically
the frontal lobes, the insula, and the anterior cingulate cortex (Pan et al.
2012; Schroeter et al. 2007; Whitwell et al. 2009). For nfvPPA the
atrophy is predominantly left-sided in inferior-frontal and insular cor-
tices, whereas for svPPA asymmetrical (commonly left-sided) ante-
roinferior temporal lobe and temporal gyrus atrophy is normally ob-
served (Gorno-Tempini et al. 2004; Schroeter et al. 2007). Studies have
demonstrated that visual rating of atrophy patterns provide useful di-
agnostic information based on simple and reliable scales (Harper et al.
2016). However, subtle atrophy in early stages of the disease and
overlap in atrophy patterns between dementia types may reduce the
utility of such approaches (Mendez et al. 2013; Mesulam et al. 2014).
Moreover, visual image evaluation depends on the training and ex-
perience of the radiologist which may vary, especially outside specia-
lized centers (Klöppel et al. 2008).
MRI provides a multitude of data for defining different imaging
biomarkers, some of which require complicated post-processing and
image analysis (Bouts et al. 2018; Möller et al. 2015b; Steketee et al.
2016a). Current imaging biomarkers available for detecting FTD have
so far only obtained modest diagnostic performance (Canu et al. 2017;
Harper et al. 2016, 2015; Meyer et al. 2017; Möller et al. 2015b). Ac-
curacy may increase when combining different imaging biomarkers, but
the combinations are often purely data-driven (Canu et al. 2017; Meyer
et al. 2017; Möller et al. 2015a). From a clinical viewpoint such com-
binations might therefore not be intuitive or logical, whereas for clin-
icians it is preferable to operate with simple and easily understandable
biomarkers. Furthermore, research studies focus predominately on
differentiating bvFTD from AD or healthy controls, and are often per-
formed in selected cohorts. Here, the relatively low prevalence of FTD
and heterogeneity of a mixed memory population are seldom accounted
for (Canu et al. 2017; Hogan et al. 2016; Meyer et al. 2017; Möller et al.
2015a, 2015b).
The main objective of this study was to develop and validate the
diagnostic accuracy of simple automated MRI biomarkers for clinical
diagnosis of FTD. We focused on the frontotemporal atrophy patterns
for identification of an index for differentiation of FTD from all other
dementia groups (non-FTD) (Neary et al. 1998). The asymmetrical
atrophy patterns in nfvPPA and svPPA, and the anterior temporal lobe
affection in svPPA formed the basis for the indexes developed for se-
paration of PPA subtypes from non-FTD and bvFTD (Gorno-Tempini
et al. 2004; Schroeter et al. 2007). First, we studied the ability of the
biomarkers to differentiate FTD from non-FTD in a mixed memory
clinic cohort. Second, we assessed the performance when differ-
entiating FTD subtypes from one another.
2. Materials and methods
2.1. Participants
In this retrospective multicenter study, we included 1213 patients
from two memory clinic cohorts. From the Amsterdam Dementia
Cohort (ADC), which has been consecutively acquired at the Alzheimer
center Amsterdam, Amsterdam UMC between 2004 and 2014, we in-
cluded 614 patients (Van Der Flier et al. 2014; Van Der Flier and
Scheltens 2018). From the PredictND multicenter cohort, which was
based on consecutive sampling from 4 European centers, we included
599 patients (Bruun et al. 2019). This ADC+PredictND cohort con-
sisted of patients with the following diagnoses: 341 AD, 66 dementia
with Lewy bodies (DLB), 40 vascular dementia (VaD), 104 other de-
mentias (e.g. Parkinson's disease with dementia, atypical parkinsonism,
normal pressure hydrocephalus and dementia with uncertain etiology),
229 mild cognitive impairment (MCI), 317 subjective cognitive decline
(SCD), and 116 FTD patients with the following FTD subtypes: 64
bvFTD, 30 svPPA, 8 nfvPPA, 10 right temporal variant FTD (rtvFTD),
and 4 FTD with motor neuron disease (+MND). Based on purposive
sampling an independent validation cohort of 200 patients was ob-
tained from the Danish Dementia Research Centre (DDRC), Copenhagen
University Hospital – Rigshospitalet, Denmark: 110 AD, 20 DLB, 28
VaD, 18 SCD, and 24 FTD with the following subtypes: 10 bvFTD, 12
svPPA, and 2 nfvPPA. Patients were eligible for inclusion if MRI of
sufficient quality was available. For this purpose, visual inspection of
scans was performed and scans containing large artifacts, very noisy
images, and images with contrast agent were excluded.
All patients received a standardized work-up, including medical
history, physical and neurological assessment, cognitive testing, MRI,
laboratory tests, and in a subset examination of cerebrospinal fluid
(CSF) (n=883). Genetic testing for FTD genes where not performed as
part of the standard assessment. Patients were diagnosed as SCD when
the cognitive complaints were not accompanied by objectively con-
firmed cognitive impairment, and the criteria for MCI or dementia were
not met (Albert et al. 2011; McKhann et al. 2011). The National In-
stitute on Aging-Alzheimer's Association (NIA-AA) criteria were used to
diagnose patients with MCI (Albert et al. 2011) and dementia due to AD
(McKhann et al. 2011). The Neary and Snowden et al. or the Mckhann
et al. criteria were used for FTD, and the Rascovsky et al. criteria for
bvFTD and Gorno-Tempini et al. criteria for svPPA and nfvPPA (Gorno-
Tempini et al. 2011; McKhann 2001; Neary et al. 1998; Rascovsky et al.
2011). VaD was diagnosed according to the NINDS-AIREN criteria
(Román et al. 1993) and DLB to the McKeith criteria (Mckeith et al.
2005). Moreover, published criteria were used to diagnose Parkinson's
disease with dementia (Emre et al. 2007), atypical parkinsonism
(Armstrong et al. 2013; Gilman et al. 2008; Litvan et al. 1996), and
normal pressure hydrocephalus (Relkin et al. 2005). All patients had as
a minimum a 12-month clinical follow-up evaluation confirming the
diagnosis. Moreover, all patients provided written informed consent for
their data to be used for research purposes.
2.2. Image acquisition and quantification
MRI were acquired on 1 T, 1.5 T, or 3 T scanners (voxel size
0.5–1.0× 0.5–1.0× 0.5–1.5mm). In all centres, availability was the
key driver in assigning patients to different scanners. Seven patients
were excluded from the study because of imaging artifacts or noise. The
imaging biomarkers were extracted from T1-weighted images using a
multi-atlas segmentation algorithm based on (Lötjönen et al. 2010).
Using this method, the patient image and 79 atlases are first registered
to a template image. The 28 atlases that are most similar to the patient
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image are identified and registered to the patient image using a dense
non-rigid transformation. Finally, a probabilistic atlas is generated from
the transformed atlases and used as a spatial prior model in the ex-
pectation maximization classification algorithm. Using this algorithm
all the MRI images were segmented into 133 regions (102 cortical and
31 sub-cortical regions) of which volumes for 44 frontal, 24 temporal,
18 parietal, and 16 occipital lobe regions were used in the analysis. Of
these 102 cortical regions half were from the left side and half from the
right side.
Three MRI biomarkers were derived from the segmented volumes
using z-scores. The first MRI biomarker, the anterior vs. posterior index
(API), reflects the fact that frontal and temporal brain regions are af-
fected in FTD, whereas posterior regions are relatively preserved. The
index was defined as a z-score:
=API V V µlog /A P
where VA denotes the weighted volume of all brain regions in the
frontal and temporal lobes and VP in the parietal and occipital lobes. As
the z-score should distinguish FTD from the other diagnostic groups, μ
and σ are the average and standard deviation of logVA/VP computed for
all non-FTD patients.
The two most common early-onset causes of dementia, i.e. AD and
FTD, were used to determine the weight for the volume of each region.
The weight was defined as the difference in the average volume of the
region between AD and FTD patients for the anterior regions and be-
tween FTD and AD patients for the posterior regions, divided by the
average volume of the region for all non-FTD patients. If the weight was
negative, it was set to zero. At visual inspection, the distribution of the
regions with a high weight (> 0.05) formed a compact region both in
the anterior and posterior part of the brain (See Supplemental file,
Fig. 1A). The only exceptions were the parahippocampal gyrus and the
inferior temporal gyrus, and as outliers from the anatomic pattern these
regions were excluded without affecting the performance of API sig-
nificantly. Table 1A in the Supplemental file shows the weights for all
cortical regions.
The second MRI biomarker, the asymmetry index (ASI), reflects the
fact that atrophy is often asymmetric in FTD subtypes, such as svPPA
and nfvPPA. The index was defined equally to API as a z-score:
=ASI V V µlog /L R
where VL denotes the weighted volume of all brain regions in the left
frontal and temporal lobes and VR in the right frontal and temporal
lobes, and μ and σ are the average and standard deviation of logVL/VR
computed for all non-FTD. The weights were defined in the same way as
for API.
Finally, the volume of each of the 133 cortical and sub-cortical re-
gions was tested separately as an imaging biomarker. As the left tem-
poral pole (TPL) in this analysis demonstrated highest discriminative
performance, the third MRI biomarker was defined as the volume of the
TPL (See Supplemental file, Table 2A). For consistency, TPL was
transformed into z-scores in the same way as API and ASI.
2.3. Data analysis
We assessed differences in baseline characteristics between diag-
nostic groups using analysis of variance (ANOVA), Kruskal-Wallis tests,
Fig. 1. Scatter plots including box- and whiskers plots of API, ASI and TPL versus the clinical diagnoses.
A–C) the ADC+ PredictND cohort and D-F) the DDRC cohort. The z-score of the imaging biomarker (y-axis) and clinical diagnosis (x-axis) for 1) the anterior vs.
posterior index (API), 2) the asymmetric index (ASI), and 3) volume of the temporal pole left index (TPL). If the number of cases per groups is small, n≤10, only
median is shown. Abbreviations: SCD: subjective cognitive decline, MCI: mild cognitive impairment, AD: Alzheimer's disease, VaD: vascular dementia, DLB: dementia
with Lewy bodies, Other: other dementias, bvFTD: behavior variant frontotemporal dementia, svPPA: semantic variant primary progressive aphasia, nfvPPA: non-
fluent variant PPA, rtvFTD: right temporal variant FTD, +MND: FTD with motor neuron disease.
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and Pearson χ2 tests when appropriate. All volumes were normalized
first for the head size (Buckner et al. 2004), and then for age and sex
(Cole and Green 1992). There were no missing MRI data or detection of
outliers, and all data were used in all computations. Separate training
and test sets using 10-fold cross-validation were used. Further, all three
biomarkers were tested in the independent DDRC cohort.
First, we assessed the performance of the three imaging biomarkers
for separation of FTD from all non-FTD diagnostic groups (AD, DLB,
VaD, other dementias, MCI, and SCD), and from AD separately.
Thereafter, we studied how well subtypes of FTD (bvFTD, svPPA, and
svPPA+nfvPPA) were differentiated from one another. We repeated all
analyses stratifying for age. A cut-off below/above 70 years was chosen
to achieve maximum exclusion of other diagnostic groups while
maintaining the highest number of FTD cases. We used the following
performance metrics: sensitivity, specificity, and area under the re-
ceiver operating characteristic curve (AUC). To account for the low
prevalence of FTD in clinical practice we chose a cut-off value that leads
to a specificity about 95%. For normally distributed variables, such as
API, a specificity of 95% is obtained with the cut-off value z=−1.65,
i.e. all cases with API < −1.65 are classified as FTD in the analysis.
When the classification of subtypes was studied, the constraint for high
specificity was less relevant. In this analysis, an optimal cut-off value
maximizing the average of sensitivity and specificity was defined.
Additionally, as 1 T images typically have lower signal-to-noise ra-
tion and contrast, we compared results with and without 1 T images. In
addition to age and sex correction, we also studied the correction for
the MRI field strength (1 T, 1.5 T, and 3 T). However, these additional
analyses did not significant impact on the accuracy and are presented in
the Supplemental file, Table 3-4A.
Finally, we explored differences between bvFTD cases with
API < −1.65 versus API > −1.65 as an API value above the cut-off
value indicates a less pronounced frontotemporal atrophy pattern. First,
we explored the relationship between amyloid-β and API using scatter
plots. Second, we used the cluster analysis approach described in
(Whitwell et al. 2009) and (Ranasinghe et al. 2016) to investigate
distinct anatomic patterns. The modulated gray matter (GM) volumes of
18 regions of interest (ROIs) were defined from the ADC+PredictND
cohort (Ranasinghe et al. 2016). Thereafter, hierarchical agglomerative
cluster analysis was used to generate the clusters of atrophy patterns for
the bvFTD cases (Whitwell et al. 2009). We analyzed the GM atrophy
patterns of the bvFTD clusters relative to SCD and AD. All the analyses




The baseline characteristics of the ADC+PredictND and DDRC
cohorts, including FTD subtypes, are presented in Table 1 (See Sup-
plemental file for additional details, Table 5A).
3.2. Performance of API, ASI, and TPL
Table 2 shows sensitivity, specificity, and AUC computed for the
ADC+PredictND cohort for all patients and for patients below 70 years
of age. Only the imaging biomarkers with the highest performance for
each classification are presented (See Supplemental file for additional
results, Tables 2A, 6-7A). At the required specificity close to 95%, API
separated FTD from non-FTD with a sensitivity of 59% (AUC=83%)
(See Supplemental file for performances at other specificities,
Table 8A). When separating FTD from AD the performance of API was
almost the same (AUC=82%). Further, we found that API performed
with slightly higher sensitivity (63%) and AUC (87% for non-FTD and
88% for AD) when applied to patients below 70 years. ASI performed
with 79% sensitivity and 92% specificity (AUC=85%) for separation
of svPPA+nfvPPA from bvFTD, whereas TPL separated svPPA from
bvFTD with 82% sensitivity and 80% specificity (AUC=85%). For the
same diagnostic comparisons ASI performed slightly better
(AUC=88%) and TPL slightly worse (AUC=83%) in the cohort<
70 years.
When the model was applied to the independent DDRC cohort, the
performance of API for detection of FTD from non-FTD (AUC=85%)
and TPL for separation of svPPA from bvFTD (AUC=97%) were
comparable to the original results (Table 2). In contrast, the perfor-
mance of ASI for separation of svPPA+nfvPPA from bvFTD decreased
from an AUC of 85% to 68% (Table 2).
Scatter plots including box-and-whiskers plots for the different
imaging biomarkers and diagnostics groups are shown in Fig. 1. The
plots show that API provides high separation of FTD from non-FTD but
little separation with regards to FTD subtypes. Both ASI and TPL per-
form better than API with regards to separation of the FTD subtypes
svPPA and nfvPPA.
Fig. 2 shows the receiver operating characteristic (ROC) curves for
the ADC+PredictND cohort and DDRC cohort.
3.3. Exploration of bvFTD cases with API values above the cut-off value
An API value above the cut-off value indicating less pronounced
frontotemporal atrophy pattern was observed in half of the bvFTD
cases. Data showed a difference in age, trail making test B (TMT) and
total cortical gray matter volume (CGM) between the group of bvFTD
cases below the cut-off value compared to the group above:
API < −1.65 (n=32, age: 62 ± 6, TMT-B: 169 ± 184 s, CGM:
429 ± 36ml) and API > −1.65 (n= 32, age: 65 ± 8 (p=0.04),
TMT-B: 238 ± 125 s (p=0.004), CGM: 480 ± 42ml (p=0.02)) (See
Supplemental file, Table 9A). When exploring the relationship between
amyloid-β and API, we found no difference between the two groups in
terms of CSF findings reflecting amyloid pathology (See Supplemental
file, Fig. 2A). Thereafter, a cluster analysis was performed to assess
heterogeneity of anatomic patterns in the bvFTD cases as shown in
Fig. 3. When comparing bvFTD with SCD we identified 4 clusters: a)
frontal and temporal gray matter loss with subcortical involvement, b)
frontal atrophy and subcortical involvement, c) temporal and modest
subcortical involvement, and d) predominantly subcortical atrophy.
Moreover, the result showed that the subcortical cluster group con-
tained>80% of the API > −1.65 cases. When comparing bvFTD and
AD we found no differences between the subcortical bvFTD and AD
cases demonstrating a very similar atrophy pattern for these two
groups.
4. Discussion
In this retrospective multicenter study, we developed three diag-
nostic imaging biomarkers (API, ASI, and TPL), derived from volu-
metric MRI, for diagnosis of FTD and separation of FTD subtypes. API
performed with an AUC of 83% and 82% when detecting FTD from non-
FTD and AD patients, respectively. A distinct frontotemporal atrophy
pattern was detectable in 59% of all FTD patients, whereas a large
proportion of the remaining FTD cases demonstrated a subcortical
atrophy pattern similar to AD. ASI showed highest performance for
detecting the two PPA subtypes, whereas TPL was specific for detection
of svPPA.
Since the prevalence of FTD is relatively low (accounts for ap-
proximately 3% of all dementia and 10% of early-onset dementia), an
imaging biomarker should perform with a high specificity to avoid false
positive FTD diagnoses in clinical practice (Hogan et al. 2016). For
detection of FTD using API we therefore aimed for a high specificity
with the trade-off of a moderate-low sensitivity, although still com-
parable to other MRI derived biomarkers with lower specificity (Bouts
et al. 2018; Harper et al. 2016; Muñoz-Ruiz et al. 2012; Steketee et al.
2016a). Compared to API, studies with advanced MRI methods, such as
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voxel-based morphometry, resting state functional MRI, diffusion
tensor imaging (DTI), and arterial spin labelling (ASL) have for single
imaging biomarkers shown equal or lower AUC ranging from 61 to 81%
(Accuracy: 72–79%, Sensitivity: 60–83%, Specificity: 63–93%) when
differentiating between AD and FTD (Bouts et al. 2018; Bron et al.
2017; Cajanus et al. 2018; Canu et al. 2017; Klöppel et al. 2015; Möller
et al. 2015b; Muñoz-Ruiz et al. 2012; Steketee et al. 2016a). Our study
presents relatively simple MRI atrophy biomarkers readily applicable to
clinical practice as an additional tool in the clinicians´ armamentarium.
Supporting this, in another study comparing the performance of dif-
ferent commonly used diagnostic tests (cognitive tests, CSF biomarkers,
and automated MRI features) we found that API performed at com-
parable or better levels than most tests for separation of FTD from other
dementia groups (Bruun et al. 2018).
Separating bvFTD from AD is often difficult (Mendez et al. 2013;
Neary et al. 1998). In the present study, the performance of API when
separating FTD from non-FTD and from AD was comparable. However,
visually the scatter plots show a smaller difference between bvFTD and
AD. This may be due to the fact that both groups may present with
atrophy in the temporal lobe and that atypical atrophy patterns are
frequent in AD (Lehmann et al. 2012; Ossenkoppele et al. 2015; van de
Pol 2006). Furthermore, a frontal variant of AD also exist (McKhann
et al. 2011). The performance of API increased when applied only to
patients below 70 years of age indicating that the index might perform
better in this subgroup. This could be due to the fact that AD more often
presents as posterior cortical atrophy in the younger AD population, or
that focal atrophy may be attenuated by the effect of age-related global
atrophy in older adults (Ge et al. 2002; Steketee et al. 2016a).
Only a few studies using imaging biomarkers have addressed sub-
typing of FTD (Agosta et al. 2015; Canu et al. 2017; Meyer et al. 2017;
Möller et al. 2015b, 2015a), although correct classification of subtypes
is important regarding prognosis, supportive measures, and patient
information. In this study, we found high performance of ASI and TPL
for separation of svPPA+nfvPPA from bvFTD, and specifically TPL for
detection of svPPA. However, due to the small numbers of nfvPPA the
results combining svPPA+nfvPPA are subject to some uncertainty and
must be interpreted with caution. Nevertheless, the atrophy patterns of
FTD subtypes with predominantly asymmetrical affection in nfvPPA
and svPPA, and temporal affection in svPPA seem to be a rational ap-
proach for separation of PPA subtypes from non-FTD and bvFTD
(Gorno-Tempini et al. 2004; Schroeter et al. 2007).
When validating the three biomarkers in the independent DDRC
cohort the result for API and TPL seemed to be generalizable. In con-
trast, for ASI the performance decreased. However, this could as well be
due to the small number of FTD cases in the DDRC cohort rather than
lack of generalization and should be retested in a larger FTD cohort.
A considerable number of bvFTD cases presented without severe
frontotemporal atrophy (API above the cut-off value, i.e. false negative
Table 1
Baseline characteristics of the ADC+PredictND and DDRC cohort.
non-FTD
FTD AD DLB VaD Other MCI SCD
A) All cases
ADC+PredictND (n=1213)
Number of patients 116 341 66 40 104 229 317
Female, n (%) 50 (43) 190 (56)†† 10 (15)† 15 (38) 53 (51) 87 (38) 173 (55)††
Age (years), mean (SD) 64 (7)† 68 (8) 69 (8) 71 (8) 73 (9)ⱡ 67 (8) 62 (9)†
MMSE, mean (SD) 24 (5) 22 (5)† 24 (4) 24 (4) 25 (4) 27 (2)† 29 (1)†
AB42, pg/ml 881 (291)† 531 (167)† 730 (258) 700 (263) 729 (335) 751 (310) 920 (251)†
Total tau, pg/ml 395 (260) 695 (407)† 341 (213) 305 (160) 480 (271) 443 (260) 290 (166)††
P tau, pg/ml 51 (25) 86 (39)† 51 (27) 44 (20) 65 (31) 66 (33) 49 (20)††
DDRC (n= 200)
Number of patients 24 110 20 28 0 0 18
Female, n (%) 9 (38) 68 (62)† 7 (35) 11 (39) – – 6 (33)
Age (years), mean (SD) 68 (10) 72 (10) 72 (9) 72 (8) – – 63 (7)†
MMSE, mean (SD) 25 (4) 24 (4) 24 (4) 25 (4) – – 29(2)†
FTD
bvFTD svPPA rtvFTD nfvPPA +MND
B) FTD cases
ADC+PredictND (n=116)
Number of patients 64 30 10 8 4
Female, n. (%) 28 (44) 14 (47) 3 (30) 3 (38) 2 (50)
Age (years), mean (SD) 63 (7) 63 (6) 63 (7) 70 (6) 62 (6)
MMSE, mean (SD) 24 (4) 22 (6) 27 (3) 23 (7) 22 (5)
AB42, pg/ml 923 (269)⁎ 780 (281) 955 (297) 685 (385) 1123 (249)
Total tau, pg/ml 390 (307) 387 (216) 385 (106) 452 (236) 470 (177)
P tau, pg/ml 51 (28) 52 (26) 45 (13) 62 (23) 39 (6)
DDRC (n=24)
Number of patients 10 12 0 2 0
Female, n. (%) 3 (30) 5 (42) – 1 (50) –
Age (years), mean (SD) 65 (13) 69 (7) – 72 (8) –
MMSE, mean (SD) 25 (5) 25 (5) – 23 (1) –
Abbreviations: FTD: frontotemporal dementia, AD: Alzheimer's disease, DLB: dementia with Lewy bodies, VaD: vascular dementia, Other: other dementias, MCI: mild
cognitive impairment, SCD: subjective cognitive decline, MMSE: the mini mental state examination, bvFTD: behavioral variant FTD, svPPA: semantic variant primary
progressive aphasia, rvtFTD: right temporal variant FTD, nfvPPA: non-fluent variant PPA, +MND: FTD+motor neuron disease.
† Differ significantly from all other groups (p < 0.05).
†† Differ significantly from MCI and VaD (p < 0.05).
ⱡ Differ from MCI, AD and DLB.
⁎ Differ from svPPA.
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cases). The diagnostic uncertainty when using clinical diagnoses
without post-mortem confirmation of the underlying neuropathology
and co-occurrence of other pathologies, should be considered
(Brunnström and Englund 2009; Mendez et al. 2013; Toledo et al.
2012). No difference in the relationship between amyloid-β and API
was though found between the bvFTD group with API values below
compared to above the cut-off value suggesting that misdiagnosis and
dual pathology are not the main reason for the false negative cases.
Contamination with FTD phenocopies should also be considered
(Steketee et al. 2016b). However, the most likely explanation is het-
erogeneity, i.e. that depending on pathological and genetic subtypes the
atrophy patterns vary (Cash et al. 2018; Rohrer et al. 2011; Whitwell
et al. 2012, 2009). Moreover, previous studies have found that a con-
siderable proportion of bvFTD does not have atrophy detectable on MRI
(Kipps et al. 2009, 2007). We performed a cluster analysis and based on
atrophy patterns identified 4 subtypes similar to what has previously
been described (Ranasinghe et al. 2016), showing that the bvFTD cases
with API > −1.65 were predominantly of the subcortical atrophy
subtype. Since API is derived from cortical atrophy patterns, it is not
ideal for detection of subcortical atrophy. Interestingly, our results
showed that the subcortical bvFTD subgroup had an atrophy pattern
similar to AD, which should be taken into account in the development
of MRI-based imaging biomarkers for these FTD cases. Future clinical
imaging biomarker studies should consider other approaches, e.g., re-
peated scans or other data, to capture this bvFTD subgroup with a more
AD-like subcortical atrophy pattern.
A strength of our study is the large ADC+PredictND multicenter
cohort containing a spectrum of diagnostic groups which is relatively
Table 2
Sensitivity, specificity and AUC computed for the ADC+PredictND and DDRC Cohort.
ADC+PredictND ALL (n= 1213) < 70 years (n=771) Imaging biomarker
sens spec AUC sens spec AUC
FTD vs. non-FTD 0.59 0.95 0.83 0.63 0.96 0.87 API
FTD vs. AD 0.59 0.93 0.82 0.63 0.95 0.88 API
svPPA+nfvPPA vs. bvFTD 0.79 0.92 0.85 0.85 0.91 0.88 ASI
svPPA+nfvPPA vs. bvFTD 0.74 0.80 0.78 0.76 0.77 0.79 TPL
svPPA vs. bvFTD 0.80 0.93 0.85 0.84 0.91 0.87 ASI
svPPA vs. bvFTD 0.82 0.80 0.85 0.82 0.77 0.83 TPL
DDRC ALL (n= 200) < 70 years (n=72)
sens spec AUC sens spec AUC
FTD vs. non-FTD 0.58 0.94 0.85 0.64 0.93 0.93 API
FTD vs. AD 0.58 0.92 0.84 0.64 0.89 0.93 API
svPPA+nfvPPA vs. bvFTD 0.29 1.00 0.68 0.43 1.00 0.86 ASI
svPPA+nfvPPA vs. bvFTD 0.79 0.90 0.91 1.00 1.00 1.00 TPL
svPPA vs. bvFTD 0.33 1.00 0.64 0.50 1.00 0.83 ASI
svPPA vs. bvFTD 0.83 0.90 0.97 1.00 1.00 1.00 TPL
Abbreviations: Sens: sensitivity, spec: specificity, AUC: the area under the receiver operating characteristic curve, FTD: frontotemporal dementia, Non-FTD: all other
diagnostic groups, bvFTD: behavioral variant FTD, svPPA: semantic variant primary progressive aphasia, nfvPPA: non-fluent variant primary progressive aphasia,
API: the anterior vs. posterior index, ASI: the asymmetric index, TPL: the temporal lobe left index.
The table presents the sensitivity, specificity and AUC in the ADC+PredictND and DDRC cohort. The results are shown for all patients, and patients< 70 years. Only
the imaging biomarkers with the highest performance for the relevant comparisons are presented (last column).
Fig. 2. Area under the ROC for API, ASI and TPL.
A) the ADC+PredictND cohort and A) the DDRC cohort. AUC values are displayed for each comparison.
Abbreviations: ROC: the receiver operator characteristic, FTD: Frontotemporal dementia, svPPA: semantic variant primary progressive aphasia, nfvPPA: non-fluent
variant PPA.
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representative of the most frequent diagnosis in a memory clinic.
However, a potentially slightly higher prevalence of the less common
diseases, e.g., FTD and DLB, might have influence the result and addi-
tional validation in a prospectively recruited cohort should be pursued.
The multicenter data was collected from>15 different scanners which
precluded us from making comparisons across scanners. However, the
use of different scanners might add to the generalizability of the bio-
markers. Another limitation of the study was the relatively few nfvPPA
and svPPA cases making it difficult to validate the TPL and ASI bio-
markers for each subtype individually. Moreover, the independent va-
lidation cohort was relatively small, and to maximize the number of
FTD cases for the age stratification a cut-off of 70 years was chosen
rather than the more commonly used definition of early-onset dementia
(i.e., 65 years). These issues underline the importance of further vali-
dation in a larger FTD cohort with especially more PPA cases. Another
issue for consideration is the possibility of circularity. In this study, MRI
scans had been used in the determination of the clinical diagnosis.
However, the derived automated MRI biomarkers were computed for
the study and had not been used for clinical diagnosis. Finally, the
clinical diagnosis is associated with some restraints due to a known
degree of discrepancy between clinical and post-mortem neuropatho-
logical diagnoses (Brunnström and Englund 2009; Mendez et al. 2013;
Schneider et al. 2009). Further, information regarding the main FTD
genes were not available for the cohorts. Performance of the biomarkers
using the neuropathological diagnosis or genetic status would therefore
be interesting to explore in future research (Cash et al. 2018; Rohrer
et al. 2011; Whitwell et al. 2012).
In conclusion, the presented MRI biomarkers were developed on the
prerequisite of clinically relevant high specificity, and API was able to
detect a distinct frontotemporal MRI pattern in 59% of all FTD patients.
Moreover, our results suggest that a considerable number of the un-
detectable bvFTD cases had a non-specific subcortical MRI pattern si-
milar to AD, and other approaches than MRI might be needed to detect
this subgroup. Finally, we found that ASI could aid in detecting svPPA
and nfvPPA, whereas TPL was more specific for svPPA. The three bio-
markers are applicable for clinical use and could provide additional
information to the diagnostic assessment and improve differential di-
agnosis of FTD in clinical practice.
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